Navigation Links
Three Surgeons in East Texas Are Successfully Integrating a Novel Stem Cell Procedure for Spine Surgeries
Date:6/5/2009

Stem Cell Technologies for Surgery

TEXARKANA, Texas, June 5 /PRNewswire/ -- A new breakthrough in adult stem cell technology has three Texarkana neurosurgeons leading their industry by utilizing concentrated stem cells for spine surgery. The innovative technique is improving the desired results of surgical interventions for back pain. Leading researchers in the orthopedic and spine industry are predicting the latest developments in this field of medicine will become mainstream practice and, potentially, a standard of care for surgical treatments of severe back pain.

Dr. Lee Buono, Dr. Freddie Contreras, and Dr. J. Brett Dietze of Texarkana Neurological Associates are utilizing the new procedure that harnesses the healing potential of adult stem cells from a patient's own body. During surgeries for the neck and back, bone marrow is extracted from the hip through a small incision. The marrow is processed by an FDA-approved device and the living cells are delivered back to the surgeon in a concentrated dose to be implanted back into a patient to promote healing.

"We pride ourselves on our ability to offer the latest medical technology, right here in Texarkana. Improving our patient's quality of life is our number-one focus. This procedure is on the cutting edge of regenerative spine surgeries; it is a resource that must be considered as a standard for healing," Dr. Buono said. Dr. Dietze adds, "Biological graft materials have become a standard accessory in neurosurgery - autologous iliac crest autograft being the gold standard. Autologous bone graft is likely traumatic and time-consuming. My personal commitment to my patients to offer the most current advancements and treatment options is also an expectation held unanimous by Texarkana Neurological Associates. This surgical approach is without arguments on the cutting edge; the potential outcomes utilizing this technology may create an option for even the most critical patient. This is minimally invasive, efficient, safe and effective. The concentrations of endothelial progenitor cells, hematopoietic stem cells, and mesenchymal stem cells have adhesion properties that ensure the cells remain localized where we need them to promote tissue growth and healing. Surprisingly, the process takes only 15-20 minutes without adding time to the surgery."

Texarkana Neurological Associates are establishing themselves as the leaders in cutting-edge surgical care. Now more patients from East Texas, Arkansas, and Louisiana will benefit from these promising procedures. Dr. Dietze, Dr. Contreras, and Dr. Buono are the first surgeons in the region to utilize the new technology and look forward to working with the local surgeons and medical staff to encourage widespread adoption to benefit all patients in need of cell therapy.

"As a neurosurgeon, I pride myself on the ability to offer my patient the most current, and proven, procedures. I am utilizing BMAC(R) from Harvest Technologies, which is truly on the cutting edge of medical technology, highly credible research from respected surgeons and top-tier institutions support its potential advantage to aid in faster healing time and favorable postoperative outcomes. BMAC(R) provides an efficacious, minimally invasive system to utilize a patient's autologous bone marrow, which science has shown to contain high numbers of adult stem cells. By concentrating these cells safely, and quickly, I can measurably increase the potential to possibly achieve exceptional outcomes. I have always committed to provide a level of skill, knowledge and care to compete with anyone in the country; I believe this product could greatly improve a patient's own natural healing potential, and positively impact their quality of life," said Dr. Contreras.

As the population ages, incidents of spinal degeneration will likely continue to increase. The potential of stem cells and regenerative medicine is virtually limitless for treatments of degenerative diseases since adult stem cells have the remarkable potential to differentiate and become new tissues such as bone, tendon, cartilage and heart muscle.

Photo: http://www.ereleases.com/pr/2009-TexarkanaNeurologicalAssociates.jpg

About Texarkana Neurological Associates

Texarkana Neurological Associates provides Texarkana and the surrounding community with neurosurgical services. Dr. Contreras concentrates his practice on surgery of the spine. Dr. Dietze and Dr. Buono perform both spinal and intracranial surgical procedures.

    Contact:

    903-794-4196
    Fax: 903-792-7408
    Email: neurosurgerytx@cableone.net
   http://www.neurosurgerytexarkana.com
    1002 Texas Boulevard,
    Suite 406
    Texarkana, TX 75501

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Texarkana Neurological Associates
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
3. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
4. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
5. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
6. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
7. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
8. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
9. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
10. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
11. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical ... significant unmet medical needs in rare diseases, today announced ... webcast on Monday, April 3 during ENDO 2017, the ... Orlando, Florida , to discuss new data regarding ... TransCon PTH and TransCon CNP). Ascendis is ...
(Date:3/23/2017)... , March 23, 2017  A new ... and accurate identification of individuals who carry ... for a rare yet potentially deadly side effect ... bipolar disorder.  The gene HLA-B*15:02 is ... such as Stevens-Johnson syndrome and toxic epidermal necrolysis ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd ... at 10 North Broadway Avenue, will be an educational and exciting program providing ... in the management of chronic pain. , Oklahoma is in a healthcare crisis. ...
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... , ... March 23, 2017 , ... The TouchPoint Solution, ... the world to manage stress and anxiety. , “Buzzies change the way we ... and co-founder of Buzzies. , Since its launch date in December 2016, The TouchPoint ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and ... and Director, AMN Healthcare: Susan Salka , 43rd President of the United States ... Big Fight My Life In and Out of the Ring: Sugar Ray Leonard , ...
(Date:3/23/2017)... ... March 23, 2017 , ... It’s that time of year again! Time to ... summer internships , which can be frustrating when they don’t even know how ... Group, a boutique public relations firm outside of Philadelphia, have offered these three tips ...
Breaking Medicine News(10 mins):